August 19, 2020 -- BioSymetrics, Sema4, and Janssen Pharmaceuticals will use artificial intelligence (AI) to predict the onset and severity of COVID-19 among different populations.
The companies will use BioSymetrics' Contingent-AI engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease. The goal of the collaboration is to enable a vaccine and a course of treatment against SARS-CoV-2.